Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71760Full metadata record
| ???org.dspace.app.webui.jsptag.ItemTag.dcfield??? | Value | Language |
|---|---|---|
| dc.contributor.advisor | 吳明賢(Ming-Shiang Wu) | |
| dc.contributor.author | Tsung-Hsien Chiang | en |
| dc.contributor.author | 江宗賢 | zh_TW |
| dc.date.accessioned | 2021-06-17T06:08:53Z | - |
| dc.date.available | 2021-02-23 | |
| dc.date.copyright | 2021-02-23 | |
| dc.date.issued | 2020 | |
| dc.date.submitted | 2020-10-21 | |
| dc.identifier.citation | Areia, M., Carvalho, R., Cadime, A. T., Rocha Goncalves, F., Dinis-Ribeiro, M. Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies. Helicobacter. 2013 Oct;18(18):325-37. Armstrong, J. A., Wee, S. H., Goodwin, C. S., Wilson, D. H. Response of Campylobacter pyloridis to antibiotics, bismuth and an acid-reducing agent in vitro--an ultrastructural study. J Med Microbiol. 1987 Dec;24(24):343-50. Arnold, M., Park, J. Y., Camargo, M. C., Lunet, N., Forman, D., Soerjomataram, I. Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035. Gut. 2020 May;69(69):823-9. Asada, K., Nakajima, T., Shimazu, T., Yamamichi, N., Maekita, T., Yokoi, C., Oda, I., Ando, T., Yoshida, T., Nanjo, S., Fujishiro, M., Gotoda, T., Ichinose, M., Ushijima, T. Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study. Gut. 2015 Mar;64(64):388-96. Bae, S. E., Jung, H. Y., Kang, J., Park, Y. S., Baek, S., Jung, J. H., Choi, J. Y., Kim, M. Y., Ahn, J. Y., Choi, K. S., Kim, D. H., Lee, J. H., Choi, K. D., Song, H. J., Lee, G. H., Kim, J. H. Effect of Helicobacter pylori eradication on metachronous recurrence after endoscopic resection of gastric neoplasm. Am J Gastroenterol. 2014 Jan;109(109):60-7. Bair, M. J., Chuang, S. L., Lei, W. Y., Chen, C. L., Tian, H. W., Chiang, T. H., Su, W. W., Lin, C. C., Chung Lo, Y. T., Jou, Y. Y., Wu, C. Y., Chia, S. L., Wu, M. S., Chen, H. H., Chu, C. H., Lee, Y. C., Wang, Y. W. Planning mass eradication of Helicobacter pylori infection for indigenous Taiwanese peoples to reduce gastric cancer. J Gastroenterol Hepatol. 2020 Apr;35(35):609-16. Bang, C. S., Lee, J. J., Baik, G. H. Prediction of chronic atrophic gastritis and gastric neoplasms by serum pepsinogen assay: a systematic review and meta-analysis of diagnostic test accuracy. J Clin Med. 2019 May 10;8(8). Banks, M., Graham, D., Jansen, M., Gotoda, T., Coda, S., di Pietro, M., Uedo, N., Bhandari, P., Pritchard, D. M., Kuipers, E. J., Rodriguez-Justo, M., Novelli, M. R., Ragunath, K., Shepherd, N., Dinis-Ribeiro, M. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019 Sep;68(68):1545-75. Begg, C. B., Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994 Dec;50(50):1088-101. Blaser, M. J. Antibiotic use and its consequences for the normal microbiome. Science. 2016 Apr 29;352(352):544-5. Bosman FT, Carneiro F, Hruban RH, et al (Eds.): WHO Classification of Tumours of the Digestive System. IARC: Lyon 2010. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(68):394-424. Bray, F., Jemal, A., Grey, N., Ferlay, J., Forman, D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012 Aug;13(13):790-801. Bray, F., Ren, J. S., Masuyer, E., Ferlay, J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013 Mar 1;132(132):1133-45. Capelle, L. G., de Vries, A. C., Haringsma, J., Ter Borg, F., de Vries, R. A., Bruno, M. J., van Dekken, H., Meijer, J., van Grieken, N. C., Kuipers, E. J. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010 Jun;71(71):1150-8. Chen, H. N., Wang, Z., Li, X., Zhou, Z. G. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer. 2016 Jan;19(19):166-75. Chen, Q., Liang, X., Long, X., Yu, L., Liu, W., Lu, H. Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases. Helicobacter. 2019 Apr;24(24):e12563. Chen, T. H., Chiu, Y. H., Luh, D. L., Yen, M. F., Wu, H. M., Chen, L. S., Tung, T. H., Huang, C. C., Chan, C. C., Shiu, M. N., Yeh, Y. P., Liou, H. H., Liao, C. S., Lai, H. C., Chiang, C. P., Peng, H. L., Tseng, C. D., Yen, M. S., Hsu, W. C., Chen, C. H., Taiwan Community-Based Integrated Screening, G. Community-based multiple screening model: design, implementation, and analysis of 42,387 participants. Cancer. 2004 Apr 15;100(100):1734-43. Chen, T. S., Chang, F. Y., Chen, P. C., Huang, T. W., Ou, J. T., Tsai, M. H., Wu, M. S., Lin, J. T. Simplified 13C-urea breath test with a new infrared spectrometer for diagnosis of Helicobacter pylori infection. J Gastroenterol Hepatol. 2003 Nov;18(18):1237-43. Chiang, T. H., Chang, W. J., Chen, S. L., Yen, A. M., Fann, J. C., Chiu, S. Y., Chen, Y. R., Chuang, S. L., Shieh, C. F., Liu, C. Y., Chiu, H. M., Chiang, H., Shun, C. T., Lin, M. W., Wu, M. S., Lin, J. T., Chan, C. C., Graham, D. Y., Chen, H. H., Lee, Y. C. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut. 2020 Aug 13. Chiang, T. H., Chiu, S. Y., Chen, S. L., Yen, A. M., Fann, J. C., Liu, C. Y., Chou, C. K., Chiu, H. M., Shun, C. T., Wu, M. S., Lin, J. T., Lee, Y. C., Chen, T. H., Lin, M. W. Serum pepsinogen as a predictor for gastric cancer death: a 16-year community-based cohort study. J Clin Gastroenterol. 2019 May/Jun;53(53):e186-e93. Chiang, T. H., Chuang, S. L., Chen, S. L., Chiu, H. M., Yen, A. M., Chiu, S. Y., Fann, J. C., Chou, C. K., Lee, Y. C., Wu, M. S., Chen, H. H. Difference in performance of fecal immunochemical tests with the same hemoglobin cutoff concentration in a nationwide colorectal cancer screening program. Gastroenterology. 2014 Dec;147(147):1317-26. Chiang, T. H., Lee, Y. C., Liao, W. C., Chung, J. H., Chiu, H. M., Tu, C. H., Chen, S. C., Wu, M. S. Timing and risk factors for a positive fecal immunochemical test in subsequent screening for colorectal neoplasms. PLoS One. 2015;10(10):e0136890. Chiang, T. H., Lee, Y. C., Tu, C. H., Chiu, H. M., Wu, M. S. Performance of the immunochemical fecal occult blood test in predicting lesions in the lower gastrointestinal tract. CMAJ. 2011 Sep 20;183(183):1474-81. Chiang, T. H., Maeda, M., Yamada, H., Chan, C. C., Chen, S. L., Chiu, S. Y., Chen, Y. N., Chou, Y. H., Shieh, C. F., Liu, C. Y., Chiu, H. M., Chiang, H., Shun, C. T., Lin, M. W., Wu, M. S., Lin, J. T., Chen, H. H., Ushijima, T., Graham, D. Y., Lee, Y. C. Risk stratification for gastric cancer after Helicobacter pylori eradication: a population-based study on Matsu Islands. J Gastroenterol Hepatol. 2020 Jul 15. Choi, I. J., Kim, C. G., Lee, J. Y., Kim, Y. I., Kook, M. C., Park, B., Joo, J. Family history of gastric cancer and Helicobacter pylori treatment. N Engl J Med. 2020 Jan 30;382(382):427-36. Choi, I. J., Kook, M. C., Kim, Y. I., Cho, S. J., Lee, J. Y., Kim, C. G., Park, B., Nam, B. H. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018 Mar 22;378(378):1085-95. Choi, J., Kim, S. G., Yoon, H., Im, J. P., Kim, J. S., Kim, W. H., Jung, H. C. Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. Clin Gastroenterol Hepatol. 2014 May;12(12):793-800. Congdon PD. Bayesian Hierarchical Models: With Applications Using R. Second Edition. Chapman and Hall/CRC Press, 2019. Correa, P. The biological model of gastric carcinogenesis. IARC Sci Publ. 2004:301-10. Correa, P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992 Dec 15;52(52):6735-40. Correa, P., Fontham, E. T., Bravo, J. C., Bravo, L. E., Ruiz, B., Zarama, G., Realpe, J. L., Malcom, G. T., Li, D., Johnson, W. D., Mera, R. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst. 2000 Dec 6;92(92):1881-8. de Martel, C., Ferlay, J., Franceschi, S., Vignat, J., Bray, F., Forman, D., Plummer, M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012 Jun;13(13):607-15. DerSimonian, R., Laird, N. Meta-analysis in clinical trials. Control Clin Trials. 1986 Sep;7(7):177-88. Dixon, M. F., Genta, R. M., Yardley, J. H., Correa, P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996 Oct;20(20):1161-81. Doorakkers, E., Lagergren, J., Santoni, G., Engstrand, L., Brusselaers, N. Helicobacter pylori eradication treatment and the risk of Barrett's esophagus and esophageal adenocarcinoma. Helicobacter. 2020 Jun;25(25):e12688. Dore, M. P., Lu, H., Graham, D. Y. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016 May;65(65):870-8. Egger, M., Davey Smith, G., Schneider, M., Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997 Sep 13;315(315):629-34. Enomoto, S., Watanabe, M., Mukoubayashi, C., Ohata, H., Magari, H., Inoue, I., Maekita, T., Iguchi, M., Yanaoka, K., Tamai, H., Kato, J., Oka, M., Ichinose, M. Gastric cancer risk diagnosis and prevention in subjects with Helicobacter pylori-related chronic gastritis. In: Tonino P, editor. Gastritis and Gastric Cancer - New Insights in Gastroprotection, Diagnosis and Treatments. InTech; 2011. p. 179-196. Ford, A. C., Forman, D., Hunt, R. H., Yuan, Y., Moayyedi, P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014 May 20;348(348):g3174. Ford, A. C., Yuan, Y., Moayyedi, P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 2020 Mar 23. Fuccio, L., Zagari, R. M., Eusebi, L. H., Laterza, L., Cennamo, V., Ceroni, L., Grilli, D., Bazzoli, F. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med. 2009 Jul 21;151(151):121-8. Fukase, K., Kato, M., Kikuchi, S., Inoue, K., Uemura, N., Okamoto, S., Terao, S., Amagai, K., Hayashi, S., Asaka, M., Japan Gast Study, G. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008 Aug 2;372(372):392-7. Gorbach, S. L. Bismuth therapy in gastrointestinal diseases. Gastroenterology. 1990 Sep;99(99):863-75. Graham, D. Y. Helicobacter pylori eradication and metachronous gastric cancer. Clin Gastroenterol Hepatol. 2014 May;12(12):801-3. Graham, D. Y. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 2015 Apr;148(148):719-31. Graham, D. Y., Estes, M. K., Gentry, L. O. Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli-induced diarrhea in volunteers. Gastroenterology. 1983 Nov;85(85):1017-22. Graham, D. Y., Evans, D. G. Prevention of diarrhea caused by enterotoxigenic Escherichia coli: lessons learned with volunteers. Rev Infect Dis. 1990 Jan-Feb;12 Suppl 1(12 Suppl 1):S68-72. Graham, D. Y., Lee, Y. C., Wu, M. S. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014 Feb;12(12):177-86 e3; Discussion e12-3. Graham, D. Y., Shiotani, A. The time to eradicate gastric cancer is now. Gut. 2005 Jun;54(54):735-8. Graham, D. Y., Tansel, A. Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency. Clin Gastroenterol Hepatol. 2018 Jun;16(16):800-8 e7. Greenland, S. Avoiding power loss associated with categorization and ordinal scores in dose-response and trend analysis. Epidemiology. 1995 Jul;6(6):450-4. Grobbee, E. J., van der Vlugt, M., van Vuuren, A. J., Stroobants, A. K., Mundt, M. W., Spijker, W. J., Bongers, E. J. C., Kuipers, E. J., Lansdorp-Vogelaar, I., Bossuyt, P. M., Dekker, E., Spaander, M. C. W. A randomised comparison of two faecal immunochemical tests in population-based colorectal cancer screening. Gut. 2017 Nov;66(66):1975-82. Guo, Y., Zhang, Y., Gerhard, M., Gao, J. J., Mejias-Luque, R., Zhang, L., Vieth, M., Ma, J. L., Bajbouj, M., Suchanek, S., Liu, W. D., Ulm, K., Quante, M., Li, Z. X., Zhou, T., Schmid, R., Classen, M., Li, W. Q., You, W. C., Pan, K. F. Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer. Gut. 2019 Dec 19. Herrero, R., Parsonnet, J., Greenberg, E. R. Prevention of gastric cancer. JAMA. 2014 Sep 24;312(312):1197-8. Higgins, J. P., Thompson, S. G., Deeks, J. J., Altman, D. G. Measuring inconsistency in meta-analyses. BMJ. 2003 Sep 6;327(327):557-60. Household Registration Statistics Data Analysis. Department of Household Registration, Ministry of the Interior, Taiwan. Available at: https://www.ris.gov.tw/app/portal/346. Access on February 20, 2020. Hsiung, H. Y., Fann, J. C., Yen, A. M., Chen, S. L., Chiu, S. Y., Ku, T. H., Liu, T. Y., Chen, H. H., Lin, M. W. Stage-specific dietary factors associated with the Correa multistep and multifactorial process of human gastric carcinogenesis. Nutr Cancer. 2016 May-Jun;68(68):598-610. Hu, K. C., Wu, M. S., Chu, C. H., Wang, H. Y., Lin, S. C., Liu, C. C., Su, T. H., Liao, W. C., Chen, C. L., Liu, C. J., Shih, S. C. Decreased colorectal adenoma risk after Helicobacter pylori eradication: a retrospective cohort study. Clin Infect Dis. 2019 May 30;68(68):2105-13. Huang, Y. K., Yu, J. C., Kang, W. M., Ma, Z. Q., Ye, X., Tian, S. B., Yan, C. Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: a systematic review and meta-analysis. PLoS One. 2015;10(10):e0142080. Hundt, S., Haug, U., Brenner, H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med. 2009 Feb 3;150(150):162-9. Hunt, R. H., Camilleri, M., Crowe, S. E., El-Omar, E. M., Fox, J. G., Kuipers, E. J., Malfertheiner, P., McColl, K. E., Pritchard, D. M., Rugge, M., Sonnenberg, A., Sugano, K., Tack, J. The stomach in health and disease. Gut. 2015 Oct;64(64):1650-68. IARC Helicobacter pylori Working Group (2014). Helicobacter pylori Eradication as a Strategy for Gastric Cancer Prevention. Lyon, France: International Agency for Research on Cancer (IARC Working Group Reports, No. 8). Available at: http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/index.php. Accessed July 8, 2020. Jun, J. K., Choi, K. S., Lee, H. Y., Suh, M., Park, B., Song, S. H., Jung, K. W., Lee, C. W., Choi, I. J., Park, E. C., Lee, D. Effectiveness of the Korean national cancer screening program in reducing gastric cancer mortality. Gastroenterology. 2017 May;152(152):1319-28 e7. Juni, P., Altman, D. G., Egger, M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ. 2001 Jul 7;323(323):42-6. Kato, S., Onda, M., Matsukura, N., Tokunaga, A., Matsuda, N., Yamashita, K., Shields, P. G. Genetic polymorphisms of the cancer related gene and Helicobacter pylori infection in Japanese gastric cancer patients. An age and gender matched case-control study. Cancer. 1996 Apr 15;77(77):1654-61. Kawai, T., Miki, K., Ichinose, M., Kenji, Y., Miyazaki, I., Kawakami, K., Kataoka, M., Yamagishi, T., Sofuni, A., Itoi, T., Moriyasu, F., Takagi, Y., Aoki, T., Matsubayashi, J., Mukai, K. Changes in evaluation of the pepsinogen test result following Helicobacter pylori eradication therapy in Japan. Inflammopharmacology. 2007 Feb;15(15):31-5. Kim, S. Y., Park, J. E., Lee, Y. J., Seo, H. J., Sheen, S. S., Hahn, S., Jang, B. H., Son, H. J. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 2013 Apr;66(66):408-14. Kim, Y. I., Choi, I. J., Kook, M. C., Cho, S. J., Lee, J. Y., Kim, C. G., Ryu, K. W., Kim, Y. W. The association between Helicobacter pylori status and incidence of metachronous gastric cancer after endoscopic resection of early gastric cancer. Helicobacter. 2014 Jun;19(19):194-201. Kimura, K., Takemoto, T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1(1):87-97. Kodama, M., Murakami, K., Okimoto, T., Sato, R., Uchida, M., Abe, T., Shiota, S., Nakagawa, Y., Mizukami, K., Fujioka, T. Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication. J Gastroenterol. 2012 Apr;47(47):394-403. Kosunen, T. U., Pukkala, E., Sarna, S., Seppala, K., Aromaa, A., Knekt, P., Rautelin, H. Gastric cancers in Finnish patients after cure of Helicobacter pylori infection: A cohort study. Int J Cancer. 2011 Jan 15;128(128):433-9. Kumar, S., Metz, D. C., Ellenberg, S., Kaplan, D. E., Goldberg, D. S. Risk factors and incidence of gastric cancer after detection of Helicobacter pylori infection: a large cohort study. Gastroenterology. 2020 Feb;158(158):527-36 e7. Kwon, Y. H., Heo, J., Lee, H. S., Cho, C. M., Jeon, S. W. Failure of Helicobacter pylori eradication and age are independent risk factors for recurrent neoplasia after endoscopic resection of early gastric cancer in 283 patients. Aliment Pharmacol Ther. 2014 Mar;39(39):609-18. Lambert, J. R. Pharmacology of bismuth-containing compounds. Rev Infect Dis. 1991 Jul-Aug;13 Suppl 8(13 Suppl 8):S691-5. Lambert, J. R., Midolo, P. The actions of bismuth in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1997 Apr;11 Suppl 1(11 Suppl 1):27-33. Lauren, P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64(64):31-49. Lee, Y. C., Chen, T. H., Chiu, H. M., Shun, C. T., Chiang, H., Liu, T. Y., Wu, M. S., Lin, J. T. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2013 May;62(62):676-82. Lee, Y. C., Chiang, T. H., Chou, C. K., Tu, Y. K., Liao, W. C., Wu, M. S., Graham, D. Y. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016 May;150(150):1113-24. Lee, Y. C., Chiang, T. H., Liou, J. M., Chen, H. H., Wu, M. S., Graham, D. Y. Mass eradication of Helicobacter pylori to prevent gastric cancer: theoretical and practical considerations. Gut Liver. 2016 Jan;10(10):12-26. Lee, Y. C., Lin, J. T., Wu, H. M., Liu, T. Y., Yen, M. F., Chiu, H. M., Wang, H. P., Wu, M. S., Hsiu-Hsi Chen, T. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer. Cancer Epidemiol Biomarkers Prev. 2007 May;16(16):875-85. Lee, Y. C., Wu, H. M., Chen, T. H., Liu, T. Y., Chiu, H. M., Chang, C. C., Wang, H. P., Wu, M. S., Chiang, H., Wu, M. C., Lin, J. T. A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures. Helicobacter. 2006 Oct;11(11):418-24. Leja, M., Kupcinskas, L., Funka, K., Sudraba, A., Jonaitis, L., Ivanauskas, A., Janciauskas, D., Kiudelis, G., Chiu, H. M., Lin, J. T. The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standard histopathology. Dig Dis Sci. 2009 Nov;54(54):2377-84. Leung, W. K., Lin, S. R., Ching, J. Y., To, K. F., Ng, E. K., Chan, F. K., Lau, J. Y., Sung, J. J. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut. 2004 Sep;53(53):1244-9. Leung, W. K., Wu, M. S., Kakugawa, Y., Kim, J. J., Yeoh, K. G., Goh, K. L., Wu, K. C., Wu, D. C., Sollano, J., Kachintorn, U., Gotoda, T., Lin, J. T., You, W. C., Ng, E. K., Sung, J. J., Asia Pacific Working Group on Gastric, C. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008 Mar;9(9):279-87. Li, W. Q., Ma, J. L., Zhang, L., Brown, L. M., Li, J. Y., Shen, L., Pan, K. F., Liu, W. D., Hu, Y., Han, Z. X., Crystal-Mansour, S., Pee, D., Blot, W. J., Fraumeni, J. F., Jr., You, W. C., Gail, M. H. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. J Natl Cancer Inst. 2014 Jul;106(106). Li, W. Q., Zhang, J. Y., Ma, J. L., Li, Z. X., Zhang, L., Zhang, Y., Guo, Y., Zhou, T., Li, J. Y., Shen, L., Liu, W. D., Han, Z. X., Blot, W. J., Gail, M. H., Pan, K. F., You, W. C. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ. 2019 Sep 11;366(366):l5016. Liou, J. M., Chen, C. C., Chang, C. M., Fang, Y. J., Bair, M. J., Chen, P. Y., Chang, C. Y., Hsu, Y. C., Chen, M. J., Chen, C. C., Lee, J. Y., Yang, T. H., Luo, J. C., Chen, C. Y., Hsu, W. F., Chen, Y. N., Wu, J. Y., Lin, J. T., Lu, T. P., Chuang, E. Y., El-Omar, E. M., Wu, M. S., Taiwan Gastrointestinal, D., Helicobacter, C. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infect Dis. 2019 Oct;19(19):1109-20. Liou, J. M., Chen, C. C., Chang, C. Y., Chen, M. J., Chen, C. C., Fang, Y. J., Lee, J. Y., Yang, T. H., Luo, J. C., Wu, J. Y., Liou, T. C., Chang, W. H., Hsu, Y. C., Tseng, C. H., Chang, C. C., Bair, M. J., Liu, T. Y., Hsieh, C. F., Tsao, F. Y., Shun, C. T., Lin, J. T., Lee, Y. C., Wu, M. S., Taiwan Gastrointestinal, D., Helicobacter, C. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial. Gut. 2016 Nov;65(65):1784-92. Liou, J. M., Fang, Y. J., Chen, C. C., Bair, M. J., Chang, C. Y., Lee, Y. C., Chen, M. J., Chen, C. C., Tseng, C. H., Hsu, Y. C., Lee, J. Y., Yang, T. H., Luo, J. C., Chang, C. C., Chen, C. Y., Chen, P. Y., Shun, C. T., Hsu, W. F., Hu, W. H., Chen, Y. N., Sheu, B. S., Lin, J. T., Wu, J. Y., El-Omar, E. M., Wu, M. S., Taiwan Gastrointestinal, D., Helicobacter, C. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2016 Nov 12;388(388):2355-65. Liu, C. Y., Wu, C. Y., Lin, J. T., Lee, Y. C., Yen, A. M., Chen, T. H. Multistate and multifactorial progression of gastric cancer: results from community-based mass screening for gastric cancer. J Med Screen. 2006;13 Suppl 1(13 Suppl 1):S2-5. Mabe, K., Takahashi, M., Oizumi, H., Tsukuma, H., Shibata, A., Fukase, K., Matsuda, T., Takeda, H., Kawata, S. Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer? World J Gastroenterol. 2009 Sep 14;15(15):4290-7. Machado, A. M., Figueiredo, C., Touati, E., Maximo, V., Sousa, S., Michel, V., Carneiro, F., Nielsen, F. C., Seruca, R., Rasmussen, L. J. Helicobacter pylori infection induces genetic instability of nuclear and mitochondrial DNA in gastric cells. Clin Cancer Res. 2009 May 1;15(15):2995-3002. Maeda, M., Nakajima, T., Oda, I., Shimazu, T., Yamamichi, N., Maekita, T., Asada, K., Yokoi, C., Ando, T., Yoshida, T., Nanjo, S., Fujishiro, M., Gotoda, T., Ichinose, M., Ushijima, T. High impact of methylation accumulation on metachronous gastric cancer: 5-year follow-up of a multicentre prospective cohort study. Gut. 2017 Sep;66(66):1721-3. Maeda, M., Yamashita, S., Shimazu, T., Iida, N., Takeshima, H., Nakajima, T., Oda, I., Nanjo, S., Kusano, C., Mori, A., Moro, H., Yamada, H., Tsugane, S., Sugiyama, T., Sakai, Y., Ushijima, T. Novel epigenetic markers for gastric cancer risk stratification in individuals after Helicobacter pylori eradication. Gastric Cancer. 2018 Sep;21(21):745-55. Maehata, Y., Nakamura, S., Fujisawa, K., Esaki, M., Moriyama, T., Asano, K., Fuyuno, Y., Yamaguchi, K., Egashira, I., Kim, H., Kanda, M., Hirahashi, M., Matsumoto, T. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc. 2012 Jan;75(75):39-46. Malfertheiner, P., Megraud, F., O'Morain, C. A., Gisbert, J. P., Kuipers, E. J., Axon, A. T., Bazzoli, F., Gasbarrini, A., Atherton, J., Graham, D. Y., Hunt, R., Moayyedi, P., Rokkas, T., Rugge, M., Selgrad, M., Suerbaum, S., Sugano, K., El-Omar, E. M., European, H., Microbiota Study, G., Consensus, p. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 Jan;66(66):6-30. Manhart, M. D. In vitro antimicrobial activity of bismuth subsalicylate and other bismuth salts. Rev Infect Dis. 1990 Jan-Feb;12 Suppl 1(12 Suppl 1):S11-5. Marcus, E. A., Sachs, G., Scott, D. R. Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth-dependent antibiotics. Aliment Pharmacol Ther. 2015 Oct;42(42):922-33. Miki, K., Urita, Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis. 2007 Feb;8(8):8-14. Miyahara, R., Niwa, Y., Matsuura, T., Maeda, O., Ando, T., Ohmiya, N., Itoh, A., Hirooka, Y., Goto, H. Prevalence and prognosis of gastric cancer detected by screening in a large Japanese population: data from a single institute over 30 years. J Gastroenterol Hepatol. 2007 Sep;22(22):1435-42. Mizuno, S., Kobayashi, M., Tomita, S., Miki, I., Masuda, A., Onoyama, M., Habu, Y., Inokuchi, H., Watanabe, Y. Validation of the pepsinogen test method for gastric cancer screening using a follow-up study. Gastric Cancer. 2009;12(12):158-63. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009 Aug 18;151(151):264-9, W64. Nakagawa, S., Asaka, M., Kato, M., Nakamura, T., Kato, C., Fujioka, T., Tatsuta, M., Keida, K. Helicobacter pylori eradication and metachronous gastric cancer after endoscopic mucosal resection of early gastric cancer. Aliment Pharmacol Ther. 2006;24 Suppl 4(24 Suppl 4):214-8. National Cancer Registry: On-line Interactive Data Acquisition System, Health Promotion Administration, Ministry of Health and Welfare, Taiwan. Available at: https://cris.hpa.gov.tw/. Access on February 20, 2020. Nomura, A. M., Kolonel, L. N., Miki, K., Stemmermann, G. N., Wilkens, L. R., Goodman, M. T., Perez-Perez, G. I., Blaser, M. J. Helicobacter pylori, pepsinogen, and gastric adenocarcinoma in Hawaii. J Infect Dis. 2005 Jun 15;191(191):2075-81. Ogura, K., Hirata, Y., Yanai, A., Shibata, W., Ohmae, T., Mitsuno, Y., Maeda, S., Watabe, H., Yamaji, Y., Okamoto, M., Yoshida, H., Kawabe, T., Omata, M. The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. J Clin Gastroenterol. 2008 Mar;42(42):279-83. Ohkusa, T., Miwa, H., Nomura, T., Asaoka, D., Kurosawa, A., Sakamoto, N., Abe, S., Hojo, M., Terai, T., Ogihara, T., Sato, N. Improvement in serum pepsinogens and gastrin in long-term monitoring after eradication of Helicobacter pylori: comparison with H. pylori-negative patients. Aliment Pharmacol Ther. 2004 Jul;20 Suppl 1(20 Suppl 1):25-32. Park, C. H., Kim, E. H., Jung, D. H., Chung, H., Park, J. C., Shin, S. K., Lee, S. K., Lee, Y. C. The new modified ABCD method for gastric neoplasm screening. Gastric Cancer. 2016 Jan;19(19):128-35. Phillips, R. H., Whitehead, M. W., Lacey, S., Champion, M., Thompson, R. P., Powell, J. J. Solubility, absorption, and anti-Helicobacter pylori activity of bismuth subnitrate and colloidal bismuth subcitrate: in vitro data do not predict in vivo efficacy. Helicobacter. 2000 Sep;5(5):176-82. Quasi-Experiments: Interrupted Time-Series Designs. In: Cook TD, Campbell DT, eds. Quasi-Experimentation: Design Analysis Issues for Field Settings. Houghton Mifflin Co, Boston;1979:207-32. Rabeneck, L., Lansdorp-Vogelaar, I. Assessment of a cancer screening program. Best Pract Res Clin Gastroenterol. 2015 Dec;29(29):979-85. Roman, L. D., Lukyanchuk, R., Sablin, O. A., Araslanova, E. I., Eklund, C., Hendolin, P., Paloheimo, L., Syrjanen, K. Prevalence of H. pylori infection and atrophic gastritis in a population-based screening with serum biomarker panel (GastroPanel®) in St. Petersburg. Anticancer Res. 2016 Aug;36(36):4129-38. Rugge, M., Meggio, A., Pennelli, G., Piscioli, F., Giacomelli, L., De Pretis, G., Graham, D. Y. Gastritis staging in clinical practice: the OLGA staging system. Gut. 2007 May;56(56):631-6. Rugge, M., Meggio, A., Pravadelli, C., Barbareschi, M., Fassan, M., Gentilini, M., Zorzi, M., Pretis, G., Graham, D. Y., Genta, R. M. Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. Gut. 2019 Jan;68(68):11-7. Saito, D., Boku, N., Fujioka, T., Fukuda, Y., Matsushima, Y., Sakaki, N., Sato, K., Sugiyama, T., Takahashi, S., Sato, T., Emura, F., Gotoda, T., Wakabayashi, K., Kakizoe, T. Impact of H. pylori eradication on gastric cancer prevention: endoscopic results of the Japanese Intervention Trial. Gastroenterology. 2005;128(128):A4. Saito, K., Arai, K., Mori, M., Kobayashi, R., Ohki, I. Effect of Helicobacter pylori eradication on malignant transformation of gastric adenoma. Gastrointest Endosc. 2000 Jul;52(52):27-32. Samloff, I. M. Immunologic studies of human group I pepsinogens. J Immunol. 1971 Apr;106(106):962-8. Samloff, I. M., Varis, K., Ihamaki, T., Siurala, M., Rotter, J. I. Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology. 1982 Jul;83(83):204-9. Seo, J. Y., Lee, D. H., Cho, Y., Lee, D. H., Oh, H. S., Jo, H. J., Shin, C. M., Lee, S. H., Park, Y. S., Hwang, J. H., Kim, J. W., Jeong, S. H., Kim, N., Jung, H. C., Song, I. S. Eradication of Helicobacter pylori reduces metachronous gastric cancer after endoscopic resection of early gastric cancer. Hepatogastroenterology. 2013 Jun;60(60):776-80. Shikata, K., Ninomiya, T., Yonemoto, K., Ikeda, F., Hata, J., Doi, Y., Fukuhara, M., Matsumoto, T., Iida, M., Kitazono, T., Kiyohara, Y. Optimal cutoff value of the serum pepsinogen level for prediction of gastric cancer incidence: the Hisayama Study. Scand J Gastroenterol. 2012 Jun;47(47):669-75. Shimoyama, T., Aoki, M., Sasaki, Y., Matsuzaka, M., Nakaji, S., Fukuda, S. ABC screening for gastric cancer is not applicable in a Japanese population with high prevalence of atrophic gastritis. Gastric Cancer. 2012 Jul;15(15):331-4. Shiotani, A., Haruma, K., Graham, D. Y. Metachronous gastric cancer after successful Helicobacter pylori eradication. World J Gastroenterol. 2014 Sep 7;20(20):11552-9. Shiotani, A., Uedo, N., Iishi, H., Yoshiyuki, Y., Ishii, M., Manabe, N., Kamada, T., Kusunoki, H., Hata, J., Haruma, K. Predictive factors for metachronous gastric cancer in high-risk patients after successful Helicobacter pylori eradication. Digestion. 2008;78(78):113-9. Siegel, R. L., Miller, K. D., Jemal, A. Cancer Statistics, 2017. CA Cancer J Clin. 2017 Jan;67(67):7-30. Stratton, C. W., Warner, R. R., Coudron, P. E., Lilly, N. A. Bismuth-mediated disruption of the glycocalyx-cell wall of Helicobacter pylori: ultrastructural evidence for a mechanism of action for bismuth salts. J Antimicrob Chemother. 1999 May;43(43):659-66. Sugano, K. Screening of gastric cancer in Asia. Best Pract Res Clin Gastroenterol. 2015 Dec;29(29):895-905. Sugano, K., Tack, J., Kuipers, E. J., Graham, D. Y., El-Omar, E. M., Miura, S., Haruma, K., Asaka, M., Uemura, N., Malfertheiner, P., faculty members of Kyoto Global Consensus, C. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015 Sep;64(64 | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71760 | - |
| dc.description.abstract | 胃癌是全球主要的健康威脅，估計每年在全球造成超過80萬人死亡。馬祖列島是我國胃癌發生高風險區域，也因此，如果有可使用之胃癌風險特異性的生物標誌物（例如血清胃蛋白酶原（PG））來識別將來發生胃癌之高風險族群，進而安排後續之內視鏡監測，則可以有效降低胃癌的死亡率。在1995年至1998年間，在馬祖地區曾進行一項以PG為主之胃癌篩檢計劃，而我們運用當時的PG檢測結果來檢視16年後(2010年)，其與發生胃癌死亡的關聯性。結果顯示PG-I <30μg/ L〔風險比率：3.27（95％信賴區間：1.11-9.61）〕和PG-I <30μg/ L或PG-I / II比<3〔風險比率：3.45（95％信賴區間：1.18-10.12）〕與胃癌死亡的風險顯著相關。目前已知幽門螺旋桿菌感染是造成胃癌最重要的病因，而根除這種病原體則可能是減輕胃癌負擔的一種策略。因為根除幽門螺旋桿菌在具有不同水平的胃癌風險和不同臨床情況的人群中獲益的程度尚不清楚，因此我們對隨機對照試驗和觀察性研究進行了系統性的回顧和統合分析，以研究根除幽門螺旋桿菌對胃癌發生率的影響。此統合分析所納入的文獻包括二十四篇符合條件的研究（22篇研究論文和2篇摘要）（總共為48,064人/ 340,255人年，且共有715例胃癌）。結果顯示，根除治療後對無症狀幽門螺旋桿菌感染者（胃癌發生率，0.62； 95％信賴區間：0.49-0.79）與已經由內視鏡切除早期胃癌後的幽門螺旋桿菌感染者（胃癌發生率，0.46； 95％信賴區間：0.35-0.60）皆提供了顯著預防胃癌發生的益處。 儘管目前研究已提出大規模根除幽門螺旋桿菌可作為消除胃癌發生的可行策略，但其對於基於以人群為基礎之幽門螺旋桿菌篩檢與治療後的長期效果仍不清楚。馬祖列島是我國胃癌發生高風險區域，針對該區域年齡大於30歲的居民以幽門螺旋桿菌的大規模根除來達到防治胃癌計畫始於2004年；而直到2018年為止，該地區已進行了6輪的大規模幽門螺旋桿菌篩檢與根除治療。與1995年至2003年的非除菌之歷史控制時期相比，我們發現，在除菌計畫進行後能有效降低胃癌的發生率〔胃癌發生率：0.53（95％信賴區間：0.30-0.69）〕。不過對於胃癌死亡率的影響，則須更長時期的追蹤才能看到效益。在大規模的幽門螺旋桿菌根除治療後，接著，我們於2015年至2018年間亦進行一前瞻篩檢計畫，包含第一階段血清學檢查（PG-1，PG-II，幽門螺旋桿菌免疫球蛋白G和胃泌素17）和第二階段內視鏡檢查。而指標性病變則包括了胃癌及萎縮性胃炎與腸化生之癌前病變，來評估血清學檢測對於幽門螺旋桿菌根除治療後來識別胃癌或癌前病變之效益。以分別根據正似然比和負似然比“排除”和“排除”風險。此外，對於有接受內視鏡檢查的居民，我們也檢測了胃黏膜組織中之microRNA-124a-3的甲基化程度，以驗證表觀遺傳標記對於胃癌風險預測的表現。結果顯示，PG檢查可以適度預測萎縮性胃炎〔陽性概似比：4.11（95％信賴區間：2.92-5.77）；陰性概似比：0.14（95％信賴區間：0.10–0.19）〕。胃泌素17則無效（陽性概似比：0.66；陰性概似比：1.20）。但是，PG檢測仍無法很好地整體預測指標性病變〔陽性概似比：2.04（95％信賴區間：1.21-3.42）；陰性概似比：0.57（95％信賴區間：0.34-0.95）〕。而表觀遺傳標記中的DNA甲基化程度則對於預測指標性病變更具識別度〔陽性概似比：3.89（95％信賴區間：2.32-6.54）；陰性概似比：（95％信賴區間：0.15-0.42）〕。 目前常規的根除幽門螺旋桿菌通常需要7-14天的療程，包括有效的抑胃酸劑和2至3種抗生素的使用。儘管充分的胃酸抑制能達到優化抗生素的殺菌作用，但是胃酸的抑制與否對鉍劑的殺菌作用有何影響尚不明確。我們運用隨機分派的設計，藉由穿透式射電子顯微鏡來直接觀察胃黏膜組織上幽門螺旋桿菌的形態學變化，並證明了鉍劑在胃內的治療幽門螺旋桿菌時的即時毒性作用與胃酸抑制與否無關。 | zh_TW |
| dc.description.abstract | Gastric cancer is a major global health threat and causing an estimated >800,000 deaths per year globally. Therefore, endoscopic surveillance would be effective and efficient in reducing gastric cancer mortality if a biomarker such as serum pepsinogen (PG) is available to identify high-risk individuals and if the biomarker also is specific to gastric cancer risk. Between 1995 and 1998, a gastric cancer-screening program was conducted in Matsu Islands: The first stage involved PG testing, and the second stage involved upper endoscopy; then, we monitor gastric cancer death until 2010 in relation to previous PG testing. After 16 years of follow-up, the results showed that PG-I <30 μg/L and PG-I <30 μg/L or PG-I/II ratio <3 were significantly associated with the risk of gastric cancer death (hazard ratio (HR), 3.27; 95% CI, 1.11-9.61 and HR, 3.45; 95% CI, 1.18-10.12, respectively). As we know, Helicobacter pylori is the most important etiologic factor for gastric cancer, and eradicating this pathogen might represent a strategy to reduce the burden of gastric cancer. The magnitude of benefit of H. pylori eradication in populations with different levels of gastric cancer risk and in different clinical scenarios is unclear. We performed a systematic review and meta-analysis of randomized controlled trials and observational studies to investigate the effects of H. pylori eradication on the incidence of gastric cancer. Twenty-four eligible studies (22 research manuscripts and 2 abstracts) were included in our meta-analysis (715 incident gastric cancers among a total of 48,064 individuals/340,255 person-years). Eradication provided significant benefit for asymptomatic infected individuals (pooled incidence rate ratio, 0.62; 95% confidence interval (CI): 0.49-0.79) and individuals after endoscopic resection of gastric cancers (pooled incidence rate ratio, 0.46; 95% CI: 0.35-0.60). Although mass eradication of H. pylori has been proposed as a means to eliminate gastric cancer, its long-term effects for population-based cohort approach remain unclear. Mass eradication of H. pylori infection was launched in 2004 and continued until 2018 for a high-risk Taiwanese population aged 30 years or older dwelling on Matsu Islands with prevalent H. pylori infection. Test-positives for the 13C-urea breath test underwent eradication therapy. After 6 rounds of mass screening and eradication, we evaluated the effectiveness of the mass eradication in reducing two main outcomes, incidence and mortality rates of gastric cancer, until the end of 2016 and 2018, respectively. Compared with the historical control period from 1995 to 2003, the effectiveness in reducing gastric cancer incidence during the chemoprevention period was 53% (95% CI: 30-69%, P<0.001) and a significant reduction in mortality is likely to be achieved with a longer follow-up period. After mass eradication, another prospective screening program involving first-stage serological tests (PG-I, PG-II, H. pylori immunoglobin G, and gastrin-17) and second-stage endoscopic examination was launched in 2015-2018 in Matsu Islands also. We defined index lesions including gastric cancer or extensive premalignant lesions, and evaluated the performance of the serological tests to “rule in” and “rule out” the risk based on positive and negative likelihood ratios, respectively. Besides, the methylation levels of microRNA-124a-3 in the stomach were measured to indicate genetic damage. The results showed that PG testing could moderately predict atrophic gastritis [positive likelihood ratio: 4.11 (95% CI: 2.92-5.77); negative likelihood ratio: 0.14 (0.10–0.19)]. Gastrin-17 was not useful (0.66 and 1.20, respectively). However, PG testing poorly predicted the index lesions [2.04 (1.21–3.42) and 0.57 (0.34–0.95)]. DNA methylation levels in the post-eradication mucosa was more discriminative for predicting index lesions [3.89 (2.32–6.54) and 0.25 (0.15–0.42)]. Eradication of H. pylori typically requires a treatment course of 7-14 days, consisting of a potent acid suppressant and 2 to 3 kinds of antibiotics. Although adequate acid suppression is required to optimize the antibiotic effects, whether this will or will not affect the effectiveness of bismuth salts remains unclear. We used a randomized design to test the hypothesis whether the bactericidal effect of colloidal bismuth subcitrate (CBS) on the H. pylori would be affected by the intra-gastric pH, a typical condition when the eradication therapy is administered, through the direct observation of morphological changes of H. pylori using the transmission electron microscopy in the absence of antibiotics. We demonstrated that an immediate toxic effect of CBS treatment on H. pylori is documented, which is independent from the intra-gastric acidity. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-17T06:08:53Z (GMT). No. of bitstreams: 1 U0001-2110202002594100.pdf: 7630143 bytes, checksum: d27f4eb8fde7263aa0b66bc8f158624b (MD5) Previous issue date: 2020 | en |
| dc.description.tableofcontents | 封面 口試委員會審定書 謝辭 I 中文摘要 II 英文摘要 IV 目錄 VI 圖目錄 IX 表目錄 XI 第一章 INTRODUCTION 1 1.1 Gastric cancer burden and risk stratification with serum pepsinogen 1 1.1.1 What is current knowledge 1 1.1.2 Why is this research needed 1 1.2 Strategy with H. pylori eradication for gastric cancer prevention 1 1.2.1 What is current knowledge 2 1.2.2 Why is this research needed 3 1.3 Long-term impact for gastric cancer prevention after H. pylori eradication 4 1.3.1 What is current knowledge 4 1.3.2 Why is this research needed 5 1.4 Gastric cancer risk stratification after H. pylori eradication 6 1.4.1 What is current knowledge 6 1.4.2 Why is this research needed 6 1.5 Effects of bismuth salts on H. pylori with and without acid suppression 8 1.5.1 What is current knowledge 8 1.5.2 Why is this research needed 8 第二章 OBJECTIVES 10 2.1 Gastric cancer burden and risk stratification with serum pepsinogen 10 2.2 Strategy with H. pylori eradication for gastric cancer prevention 10 2.3 Long-term impact for gastric cancer prevention after H. pylori eradication 10 2.4 Gastric cancer risk stratification after H. pylori eradication 10 2.5 Effects of bismuth salts on H. pylori with and without acid suppression 10 第三章 METHODS 11 3.1 Methodology to obtain the objective 2.1 11 3.1.1 Study population and design 11 3.1.2 Serologic testing and intra-gastric histology 11 3.1.3 Outcome assessment and statistical analysis 11 3.2 Methodology to obtain the objective 2.2 13 3.2.1 Search strategy and selection criteria 13 3.2.2 Data extraction and study quality assessment 13 3.2.3 Data synthesis and analysis 14 3.3 Methodology to obtain the objective 2.3 15 3.3.1 Study population and preventive program in 2004-2018 15 3.3.2 Study design 15 3.3.3 Endoscopy, histology and antibiotic resistance assessment 15 3.3.4 Outcomes and statistical analysis 17 3.4 Methodology to obtain the objective 2.4 18 3.4.1 Study population in 2015-2018 18 3.4.2 Design of endoscopic screening program 19 3.4.3 Serological test panel 20 3.4.4 Histology 20 3.4.5 Epigenetic biomarker 21 3.4.6 Outcomes and statistical analysis 21 3.5 Methodology to obtain the objective 2.5 22 3.5.1 Study design and participant selection 22 3.5.2 Randomization and intervention 22 3.5.3 Histology and transmission electron microscopy 23 3.5.4 Outcomes, sample sizeestimarion and statistical analysis 24 第四章 RESULTS 25 4.1 Report to obtain the objective 2.1 25 4.1.1 Demographic and serologic measures 25 4.1.2 Endoscopic and histologic findings 25 4.1.3 Gastric cancer-specific mortality rate according to pepsinogen results 25 4.1.4 Regression analyses 26 4.1.5 Specificity of pepsinogen test results for death from gastric cancer 26 4.1.6 Predictive value of anti-HP IgG test and effect of eradication therapy 26 4.2 Report to obtain the objective 2.2 27 4.2.1 Literature search 27 4.2.2 Traditional random-effects meta-analysis 27 4.2.3 Mixed-effect Poisson regression meta-analysis 28 4.3 Report to obtain the objective 2.3 29 4.3.1 Population attendance and referral 29 4.3.2 H. pylori infection and reinfection rates 30 4.3.3 Prevalence rates of premalignant gastric lesions 30 4.3.4 Incidence and mortality rates of gastric cancer 30 4.3.5 Incidence rates of other digestive tract cancers 31 4.3.6 Antibiotic resistance rates 31 4.4 Report to obtain the objective 2.4 31 4.4.1 Baseline demography 31 4.4.2 Performance of the screening program 32 4.4.3 Diagnostic accuracy of serological test panel 32 4.4.4 Genetic damage evaluation 33 4.5 Report to obtain the objective 2.5 34 4.5.1 Baseline demography 34 4.5.2 H. pylori morphology by TEM investigation 34 第五章 DISCUSSION 36 5.1 Summary and discussion to obtain the objective 2.1 36 5.2 Summary and discussion to obtain the objective 2.2 39 5.3 Summary and discussion to obtain the objective 2.3 43 5.4 Summary and discussion to obtain the objective 2.4 46 5.5 Summary and discussion to obtain the objective 2.5 48 第六章 FUTURE PROSPECT 51 參考文獻 108 | |
| dc.language.iso | zh-TW | |
| dc.subject | 甲基化 | zh_TW |
| dc.subject | 胃癌 | zh_TW |
| dc.subject | 幽門螺旋桿菌 | zh_TW |
| dc.subject | 鉍劑 | zh_TW |
| dc.subject | 穿透式射電子顯微鏡 | zh_TW |
| dc.subject | 篩檢 | zh_TW |
| dc.subject | 胃蛋白酶原 | zh_TW |
| dc.subject | transmission electron microscopy | en |
| dc.subject | Helicobacter pylori | en |
| dc.subject | pepsinogen | en |
| dc.subject | screening | en |
| dc.subject | methylation | en |
| dc.subject | bismuth | en |
| dc.subject | gastric cancer | en |
| dc.title | 以人群為基礎之幽門螺旋桿菌篩檢與治療來預防胃癌及根除治療後之個人監測 | zh_TW |
| dc.title | Population-based screening and treatment of Helicobacter pylori to prevent gastric cancer and the post-eradication individual surveillance | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 109-1 | |
| dc.description.degree | 博士 | |
| dc.contributor.coadvisor | 孫家棟(Chia-Tung Shun) | |
| dc.contributor.oralexamcommittee | 陳祈玲(Chi-Ling Chen),李宜家(Yi-Chia Lee),嚴明芳(Amy Ming-Fang Yen),張吉仰(Chi-Yang Chang) | |
| dc.subject.keyword | 胃癌,幽門螺旋桿菌,胃蛋白酶原,篩檢,甲基化,鉍劑,穿透式射電子顯微鏡, | zh_TW |
| dc.subject.keyword | gastric cancer,Helicobacter pylori,pepsinogen,screening,methylation,bismuth,transmission electron microscopy, | en |
| dc.relation.page | 125 | |
| dc.identifier.doi | 10.6342/NTU202004296 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2020-10-21 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
| Appears in Collections: | 臨床醫學研究所 | |
Files in This Item:
| File | Size | Format | |
|---|---|---|---|
| U0001-2110202002594100.pdf Restricted Access | 7.45 MB | Adobe PDF |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.